We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Hepatic Artery Infusion With Oxaliplatin

This study has been withdrawn prior to enrollment.
(Investigator has left institution)
ClinicalTrials.gov Identifier:
First Posted: October 26, 2005
Last Update Posted: August 27, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Medical College of Wisconsin
Hepatic artery infusion (HAI) with oxaliplatin (OX), systemic 5 fluorouracil (5FU), and leucovorin (HAI/OX/FU) will be implemented using an interventional radiology technique to obviate the need for initial major surgery (catheter placement) in patients who have unresectable liver metastasis from colorectal cancer. The study goal is to reduce tumor size to make possible a complete resection of all lesions. Secondary goals are to reduce or eliminate the complexity usually associated with HAI, to accomplish most or all of the treatment as an outpatient, to reduce costs, and to avoid the hepatotoxicity associated with HAI/floxuridine (FUDR). Oxaliplatin has been selected because of its ease of use, known toxicology, and established efficacy in colorectal cancer.

Condition Intervention Phase
Colorectal Cancer Metastasis Liver Cancer Drug: Oxaliplatin (via HAI) Drug: 5 Fluorouracil (systemic) Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Hepatic Arterial Infusion of Oxaliplatin Clinical Trial

Resource links provided by NLM:

Further study details as provided by Medical College of Wisconsin:

Primary Outcome Measures:
  • number of patients who become eligible for total resection of metastatic liver tumor
  • overall survival of patients resected for cure versus (vs.) resected for palliation vs. not resected.

Secondary Outcome Measures:
  • toxicity
  • HAI complexity
  • cost

Enrollment: 0
Study Start Date: October 2005
Study Completion Date: August 2015
Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Detailed Description:
After entry qualification and registration patients will undergo hepatic artery catheterization via interventional radiology. The catheter will remain in place for two hours while oxaliplatin is infused and then be removed. This treatment will be followed by a 48 hour infusion of 5FU and leucovorin, generally following the principle of FOLFOX 6. These cycles of therapy will be repeated biweekly for six episodes. Hepatic tumor size will be evaluated by CT scan to determine if resectability has been established as the result of tumor size reduction. If so, the patient will be offered resection of the residual lesions in an effort to achieve long term survival.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed consent
  2. Age greater than 17 years
  3. Stage IV colorectal cancer
  4. Metastasis limited to the liver considered unresectable for cure by standard methods
  5. Completely resected primary tumor
  6. Life expectancy greater than 3 years excluding cancer
  7. Eastern Cooperative Oncology Group (ECOG) status 0, 1, 2
  8. Absolute granulocyte count greater than 1500
  9. Platelet count greater than 100,000
  10. Adequate hepatic function
  11. Adequate renal function

Exclusion Criteria:

  1. Concomitant anticancer therapy other than this protocol
  2. Gastroduodenal ulcer
  3. Pregnancy or lactation
  4. Last treatment for colon cancer less than 4 weeks from this protocol
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00244348

United States, Wisconsin
Medical College of Wisconsin/ Froedtert Hospital
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Medical College of Wisconsin
Principal Investigator: Robert K Ausman, M. D. Dept. Surgery, Medical College of Wisconsin
Principal Investigator: Edward J Quebbeman, M. D. Dept. Surgery, Medical College of Wisconsin
Principal Investigator: William S Rilling, M. D. Dept. Radiology, Medical College of Wisconsin
  More Information

ClinicalTrials.gov Identifier: NCT00244348     History of Changes
Other Study ID Numbers: HRRC#341-05
First Submitted: October 25, 2005
First Posted: October 26, 2005
Last Update Posted: August 27, 2015
Last Verified: August 2015

Keywords provided by Medical College of Wisconsin:
hepatic artery infusion
colorectal cancer
liver metastasis
5 fluorouracil

Additional relevant MeSH terms:
Colorectal Neoplasms
Neoplasm Metastasis
Liver Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Liver Diseases
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs